Business

October 28, 2013

Biogen Idec revenue up 32 percent in third quarter

Drugmaker Biogen Idec reported that sales of its new multiple sclerosis drug Tecfidera helped fuel a 32 percent jump in revenue in the third quarter.

Related content

Comments

Editor's Choice Videos